Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Salk Institute expands research to find treatments and cures for COVID-19

As the COVID-19 pandemic continues across the globe, the Salk Institute joins in efforts to understand the fundamental science behind the novel coronavirus to pave the way to treatments and cures.

30 Jun 2020

Identification of SARS-CoV-2 RNA in healthcare HVAC units

Now, a new study published on the preprint server medRxiv* in June 2020 reports that viral RNA has been found to occur in HVAC (Heating, Ventilation, and AC) units in healthcare facilities. However, it is not clear if this represents a possible mechanism of viral transmission.

30 Jun 2020

China imposes lockdowns as new coronavirus cases surge

The coronavirus disease (COVID-19) pandemic first emerged in a seafood market in Wuhan City, Hubei Province, China, in December 2019. Since then, it has spread to 188 countries and territories and infected more than 10 million people. The viral infection has so far killed more than 500,000 people worldwide.

29 Jun 2020

WHO says worst is yet to come as COVID-19 pandemic speeds up

The true number of global infections and deaths, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is likely to be significantly higher due to lack of testing. Some people are also asymptomatic, which means they had no symptoms of the illness.

29 Jun 2020

Wearable technology for health-related applications

There is more than cool looks about hip clothing for top performance: Thanks to a variety of smart technologies, high-tech clothing today is capable of analyzing body functions or actively optimizing the microclimate.

29 Jun 2020

Overactive neutrophils may drive life-threatening blood clots in some COVID-19 patients

Scientists have new evidence that overactive neutrophils--a common type of circulating immune cell--may drive the life-threatening blood clots and inflammation that occur in some patients with COVID-19.

29 Jun 2020

Clinically approved drugs could disrupt SARS-CoV-2 from hijacking cells

An international team of researchers has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.

29 Jun 2020

Sanford Burnham Prebys announces research agreement with Lilly to identify COVID-19 antibodies

Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies.

29 Jun 2020

Virus re-emergence after lockdown ends

A new report in the journal Nature Human Behaviour in June 2020 reports predictions as to the effects of removing lockdown restrictions on the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and suggests that individual responsibility concerning social distancing and other precautions could avoid the need for lockdowns.

28 Jun 2020

COVID-19 patients can rapidly generate virus-attacking T cells, shows study

Patients suffering from severe respiratory symptoms as a result of SARS-CoV-2 infection can rapidly generate virus-attacking T cells, and can increase this production over time, suggests a new study of T cells from 10 COVID-19 patients under intensive care treatment.

27 Jun 2020

Weather determines NO2 concentrations, shows study

In connection with the effects of the COVID-19 pandemic, satellite measurements made headlines showing how much the air pollutant nitrogen dioxide (NO2) had decreased in China and northern Italy.

27 Jun 2020

Montana State researcher helps develop a better understanding of COVID-19 spread

How many people in the U.S. have had COVID-19? Using a database of information collected after the 2009 H1N1 outbreak, a Montana State University researcher is helping develop a better understanding of the spread of the novel coronavirus.

26 Jun 2020

Pediatric patients more resilient against COVID-19 compared to adults

The majority of children with COVID-19 in 26 countries fared well clinically compared to adults during the first four months of the pandemic, a newly released study shows.

26 Jun 2020

BATM provides business and trading update

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

26 Jun 2020

Fatalities are very rare in children with COVID-19

Children with COVID-19 generally experience a mild disease and fatalities are very rare, according to a study of 582 patients from across Europe published today in The Lancet Child & Adolescent Health journal.

26 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Biological therapy may decrease the risk of severe COVID-19

A recent observational study by Spanish researchers, currently available on the medRxiv preprint server, suggests that patients with immune-mediated diseases who receive biological therapy may have a lower risk for severe manifestations of coronavirus disease (COVID-19).

25 Jun 2020